References

The Parkinson's-Reversing Breakthrough

What is Parkinsons Disease

Get Instant Access

1. Lezak MD. Neuropsychological Assessment. 3rd ed. New York: Oxford University Press, 1995.

2. Shaskin D, Yarnell H, Alper K. Physical, psychiatric, and psychometric studies of postencephalitic parkinsonism. J Nerv Ment Dis 1942; 96:652-662.

3. Mendez MF, VanGorp W, Cummings JL. Neuropsychiatry, neuropsychology, and behavioral neurology—a critical comparison. Neuropsychiatry Neuropsychol Behav Neurol 1995; 8(4):297-302.

4. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery. Tucson: Neuropsychology Press, 1985.

5. Sweet JJ, Moberg PJ, Suchy Y. Ten-year follow-up survey of clinical neuropsychologists: part I. Practices and beliefs. Clin Neuropsychol 2000; 14(1):18-37.

6. Poreh AM. The quantified process approach: an emerging methodology to neuropsychological assessment. Clin Neuropsychol 2000; 14(2):212-222.

7. Mattis S. Dementia Rating Scale. Odessa, FL: Psychological Assessment Resources, 1988.

8. Beck AT, Steer RA. Beck Depression Inventory. San Antonio: The Psychological Corporation, 1987.

9. Beck AT, Steer RA. Beck Anxiety Inventory. San Antonio: The Psychological Corporation, 1993.

10. Jenkinson C, Fitzpatrick R, Peto V. The Parkinson's Disease Questionnaire: User Manual for the PDQ-39, PDQ-8 and PDQ Summary Index. Oxford: Health Services Research Unit, Department of Public Health, University of Oxford, 1998.

11. Marsh L. Anxiety disorders in Parkinson's disease. Int Rev Psychiatry 2000; 12:307-318.

12. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002; 8:193-197.

13. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Recognition and treatment of depression in Parkinson's disease. J Geriatr Psychiatry Neurol 2003; 16(3):178-183.

14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3):189-198.

McKeith IG, Burn D. Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. Neurol Clin 2000; 18(4):865-902.

Lang AE, Houeto J-L, Krack P, et al. Deep brain stimulation: preoperative issues. Mov Disord 2006; 21(14):S171-S196.

Voon V, Kubu C, Krack P, Houeto J-L, Tröster A. Deep brain stimulation: neuropsychiatrie and neuropsychological issues. Mov Disord 2006; 21(14):S305-327. Dymek MP, Atchison P, Harrell L, Marson DC. Competency to consent to medical treatment in cognitively impaired patients with Parkinson's disease. Neurology 2001; 56(1):17-24.

Stern Y, Marder K, Tang MX, Mayeux R. Antecedent clinical features associated with dementia in Parkinson's disease. Neurology 1993; 43(9):1690-1692. Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely & Jones, 1817. Charcot JM. Lectures on Diseases of the Nervous System. London: New London Society, 1878.

Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004; 127(Pt 3):550-560. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65(8):1239-1245. Jacobs DM, Stern Y, Mayeux R. Dementia in Parkinson's disease, Huntington's disease, and other degenerative conditions. In: Farah MJ, Feinberg TE, eds. Patient-Based Approaches to Cognitive Neuroscience. Cambridge, MA: MIT Press, 2000:375-384. Levin BE, Llabre MM, Weiner WJ. Cognitive impairments associated with early Parkinson's disease. Neurology 1989; 39(4):557-561.

Dubois B, Pillon B. Cognitive and behavioral aspects of movement disorders. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders. 3rd ed. Baltimore: Williams & Wilkins, 1998:837-858.

McPherson S, Cummings JL. Neuropsychological aspects of Parkinson's disease and parkinsonism. In: Grant I, Adams KM, eds. Neuropsychological Assessment of Neu-ropsychiatric Disorders. 2nd ed. New York: Oxford University Press, 1996:288-311. Stern Y, Richards M, Sano M, Mayeux R. Comparison of cognitive changes in patients with Alzheimer's and Parkinson's disease. Arch Neurol 1993; 50(10):1040-1045. Lieberman A, Olanow CW, Sethi K, et al. Ropinirole Study Group. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 1998; 51(4):1057-1062.

Tröster AI, Fields JA. Parkinson's disease, progressive supranuclear palsy, corticobasal degeneration and related disorders of the frontostriatal system. In: Morgan JE, Ricker (in press). JH, eds. Textbook of Clinical Neuropsychology. New York: Psychology Press, in press. Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol 1993; 50(8):873-880.

Tröster AI, Fields JA, Koller WC. Parkinson's disease and parkinsonism. In: Coffey CE, Cummings JL, eds. Textbook of Geriatric Neuropsychiatry. 2nd ed. Washington, DC: American Psychiatric Press, 2000:559-600.

Taylor AE, Saint-Cyr JA. The neuropsychology of Parkinson's disease. Brain Cogn 1995; 28(3):281-296.

Bondi MW, Kaszniak AW, Bayles KA, Vance KT. Contributions of frontal system dysfunction to memory and perceptual abilities in Parkinson's disease. Neuropsychology 1993; 7:89-102.

Stefanova ED, Kostic VS, Ziropadja LJ, Ocic GG, Markovic M. Declarative memory in early Parkinson's disease: serial position learning effects. J Clin Exp Neuropsychol 2001; 23(5):581-591.

Tröster AI, Fields JA. Frontal cognitive function and memory in Parkinson's disease: toward a distinction between prospective and declarative memory impairments? Behav Neurol 1995; 8:59-74.

Owen AM, Doyon J, Dagher A, Sadikot A, Evans AC. Abnormal basal ganglia outflow in Parkinson's disease identified with PET. Implications for higher cortical functions. Brain 1998; 121(Pt 5):949-965.

Dagher A, Owen AM, Boecker H, Brooks DJ. The role of the striatum and hippocampus in planning: a PET activation study in Parkinson's disease. Brain 2001; 124(Pt 5):1020-1032.

39. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005; 62(9):1377-1381.

40. Bechara A, Damasio AR, Damasio H, Anderson SW. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 1994; 50(1-3):7-15.

41. Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B. Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia 2002; 40:2257-2267.

42. Cools R, Barker RA, Sahakian BJ, Robbins TW. L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia 2003; 41:1431-1441.

43. Grossman M, Carvell S, Stern MB, Gollomp S, Hurtig HI. Sentence comprehension in Parkinson's disease: the role of attention and memory. Brain Lang 1992; 42(4):347-384.

44. Lieberman P, Friedman J, Feldman LS. Syntax comprehension deficits in Parkinson's disease. J Nerv Ment Dis 1990; 178(6):360-365.

45. Skeel RL, Crosson B, Nadeau SE, Algina J, Bauer RM, Fennell EB. Basal ganglia dysfunction, working memory, and sentence comprehension in patients with Parkinson's disease. Neuropsychologia 2001; 39(9):962-971.

46. Lewis FM, Lapointe LL, Murdoch BE. Language impairment in Parkinson's disease. Aphasiology 1998; 12:193-206.

47. Globus M, Mildworf B, Melamed E. Cerebral blood flow and cognitive impairment in Parkinson's disease. Neurology 1985; 35(8):1135-1139.

48. Troyer AK, Moscovitch M, Winocur G, Leach L, Freedman M. Clustering and switching on verbal fluency tests in Alzheimer's and Parkinson's disease. J Int Neuropsychol Soc 1998; 4(2):137-143.

49. Pillon B, Deweer B, Agid Y, Dubois B. Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Arch Neurol 1993; 50(4):374-379.

50. Buytenhuijs EL, Berger HJ, Van Spaendonck KP, Horstink MW, Borm GF, Cools AR. Memory and learning strategies in patients with Parkinson's disease. Neuropsycholo-gia 1994; 32(3):335-342.

51. Weintraub D, Moberg PJ, Culbertson WC, Duda JE, Stern MB. Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. Cogn Behav Neurol 2004; 17(4):195-200.

52. Filoteo JV, Rilling LM, Cole B, Williams BJ, Davis JD, Roberts JW. Variable memory profiles in Parkinson's disease. J Clin Exp Neuropsychol 1997; 19(6):878-888.

53. Leplow B, Dierks C, Herrmann P, Pieper N, Annecke R, Ulm G. Remote memory in Parkinson's disease and senile dementia. Neuropsychologia 1997; 35(4):547-557.

54. Katai S, Maruyama T, Hashimoto T, Ikeda S. Event based and time based prospective memory in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003; 74(6):704-709.

55. Kliegel M, Phillips LH, Lemke U, Kopp UA. Planning and realisation of complex intentions in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2005; 76(11):1501-1505.

56. Sarazin M, Deweer B, Merkl A, Von Poser N, Pillon B, Dubois B. Procedural learning and striatofrontal dysfunction in Parkinson's disease. Mov Disord 2002; 17(2):265-273.

57. Ferraro FR, Balota DA, Connor LT. Implicit memory and the formation of new associations in nondemented Parkinson's disease individuals and individuals with senile dementia of the Alzheimer type: a serial reaction time (SRT) investigation. Brain Cogn 1993; 21(2):163-180.

58. Heindel WC, Salmon DP, Shults CW, Walicke PA, Butters N. Neuropsychological evidence for multiple implicit memory systems: a comparison of Alzheimer's, Hunting-ton's, and Parkinson's disease patients. J Neurosci 1989; 9(2):582-587.

59. Huberman M, Moscovitch M, Freedman M. Comparison of patients with Alzheimer's and Parkinson's disease on different explicit and implicit tests of memory. Neuropsy-chiatry Neuropsychol Behav Neurol 1994; 7:185-193.

60. Knowlton BJ, Mangels JA, Squire LR. Aneostriatal habit learning system in humans. Science 1996; 273(5280):1399-1402.

61. Bondi MW, Kaszniak AW. Implicit and explicit memory in Alzheimer's disease and Parkinson's disease. J Clin Exp Neuropsychol 1991; 13(2):339-358.

62. Alegret M, Pere V, Junque C, Valldeoriola F, Tolosa E. Visuospatial deficits in Parkinson's disease assessed by Judgment of Line Orientation Test: error analyses and practice effects. J Clin Exp Neuropsychol 2001; 23(5):592-598.

Huber SJ, Shuttleworth EC, Paulson GW. Dementia in Parkinson's disease. Arch Neurol 1986; 43(10):987-990.

Brown RG, Marsden CD. Visuospatial function in Parkinson's disease. Brain 1986; 109(Pt 5):987-1002.

Pillon B, Dubois B, Bonnet AM, et al. Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15-objects test. Neurology 1989; 39(6):762-768. Marder K, Tang MX, Cote L, Stern Y, Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995; 52(7):695-701. Mayeux R, Chen J, Mirabello E, et al. An estimate of the incidence of dementia in idio-pathic Parkinson's disease. Neurology 1990; 40(10):1513-1517.

Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005; 20(10):1255-1263.

McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65(12):1863-1872. Cummings JL. Subcortical dementia. Neuropsychology, neuropsychiatry, and patho-physiology. Brit J Psychiatry 1986; 149:682-697.

Janvin CC, Larsen JP, Salmon DP, Galasko D, Hugdahl K, Aarsland D. Cognitive profiles of individual patients with Parkinson's disease and dementia: Comparison with dementia with lewy bodies and Alzheimer's disease. Mov Disord 2006; 21:337-342. Kleiner-Fisman G, Saint-Cyr JA, Miyasaki J, Lozano A, Lang AE. Subthalamic DBS replaces levodopa in Parkinson's disease. Neurology 2002; 59(8):1293-1294. Brown RG, Marsden CD. Internal versus external cues and the control of attention in Parkinson's disease. Brain 1988; 111(Pt 2):323-345.

Wright MJ, Burns RJ, Geffen GM, Geffen LB. Covert orientation of visual attention in Parkinson's disease: an impairment in the maintenance of attention. Neuropsychologia 1990; 28(2):151-159.

Yamada T, Izyuuinn M, Schulzer M, Hirayama K. Covert orienting attention in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 1990; 53(7):593-596. Mega MS, Cummings JL. Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci 1994; 6(4):358-370.

Taylor AE, Saint-Cyr JA, Lang AE. Memory and learning in early Parkinson's disease: evidence for a "frontal lobe syndrome". Brain Cogn 1990; 13(2):211-232. Dubois B, Pillon B, Lhermitte F, Agid Y. Cholinergic deficiency and frontal dysfunction in Parkinson's disease. Ann Neurol 1990; 28(2):117-121.

Robertson C, Flowers KA. Motor set in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53(7):583-592.

Marsden CD. The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. Neurology 1982; 32(5):514-539.

Tröster AI, Fields JA, Testa JA, et al. Cortical and subcortical influences on clustering and switching in the performance of verbal fluency tasks. Neuropsychologia 1998; 36(4):295-304. Piatt AL, Fields JA, Paolo AM, Koller WC, Tröster AI. Lexical, semantic, and action verbal fluency in Parkinson's disease with and without dementia. J Clin Exp Neuropsychol 1999; 21(4):435-443.

Tröster AI, Fields JA, Paolo AM, Pahwa R, Koller WC. Visual confrontation naming in Alzheimer's disease and Parkinson's disease with dementia [abstr]. Neurology 1996; 46(2):A292-A293.

Freedman M, Rivoira P, Butters N, Sax DS, Feldman RG. Retrograde amnesia in Parkinson's disease. Can J Neurol Sci 1984; 11(2):297-301.

Paul RH, Graber JR, Bowlby DC, Testa JA, Harnish MJ, Beatty WW. Remote memory in neurodegenerative disease. In: Tröster AI, ed. Memory in Neurodegenerative Disease: Biological, Cognitive, and Clinical Perspectives. Cambridge: Cambridge University Press, 1998:184-196.

Huber SJ, Freidenberg DL, Shuttleworth EC, Paulson GW, Christy JA. Neuropsycho-logical impairments associated with severity of Parkinson's disease. J Neuropsychiatry Clin Neurosci 1989; 1(2):154-158.

Pillon B, Dubois B, Lhermitte F, Agid Y. Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson's disease, and Alzheimer's disease. Neurology 1986; 36(9):1179-1185.

88. Gnanalingham KK, Byrne EJ, Thornton A, Sambrook MA, Bannister P. Motor and cognitive function in Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry 1997; 62(3):243-252.

89. Walker Z, Allen RL, Shergill S, Katona CL. Neuropsychological performance in Lewy body dementia and Alzheimer's disease. Brit J Psychiatry 1997; 170:156-158.

90. Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer's disease and Parkinson's disease comparison groups. Neurology 1996; 47(5):1148-1152.

91. Jacobs DM, Marder K, Cote LJ, Sano M, Stern Y, Mayeux R. Neuropsychological characteristics of preclinical dementia in Parkinson's disease. Neurology 1995; 45(9):1691-1696.

92. Mahieux F, Fenelon G, Flahault A, Manifacier MJ, Michelet D, Boller F. Neuropsycho-logical prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64(2):178-183.

93. Woods SP, Tröster AI. Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease. J Int Neuropsychol Soc 2003; 9:17-24.

94. Dooneief G, Mirabello E, Bell K, Marder K, Stern Y, Mayeux R. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 1992; 49(3):305-307.

95. Hubble JP, Cao T, Hassanein RE, Neuberger JS, Koller WC. Risk factors for Parkinson's disease. Neurology 1993; 43(9):1693-1697.

96. Cole SA, Woodard JL, Juncos JL, Kogos JL, Youngstrom EA, Watts RL. Depression and disability in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1996; 8(1):20-25.

97. Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55(5):377-382.

98. Sano M, Stern Y, Williams J, Cote L, Rosenstein R, Mayeux R. Coexisting dementia and depression in Parkinson's disease. Arch Neurol 1989; 46(12):1284-1286.

99. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson's disease. J Nerv Mental Dis 1990; 178(1):27-31.

100. Fields JA, Norman S, Straits-Tröster KA, Tröster AI. The impact of depression on memory in neurodegenerative disease. In: Tröster AI, ed. Memory in Neurodegenerative Disease: Biological, Cognitive, and Clinical Perspectives. New York: Cambridge University Press, 1998:314-337.

101. Kuzis G, Sabe L, Tiberti C, Leiguarda R, Starkstein SE. Cognitive functions in major depression and Parkinson disease. Arch Neurol 1997; 54(8):982-986.

102. Norman S, Tröster AI, Fields JA, Brooks R. Effects of depression and Parkinson's disease on cognitive functioning. J Neuropsychiatry Clin Neurosci 2002; 14(1):31-36.

103. Tröster AI, Paolo AM, Lyons KE, Glatt SL, Hubble JP, Koller WC. The influence of depression on cognition in Parkinson's disease: a pattern of impairment distinguishable from Alzheimer's disease. Neurology 1995; 45(4):672-676.

104. Boller F, Marcie P, Starkstein S, Traykov L. Memory and depression in Parkinson's disease. Eur J Neurol 1998; 5(3):291-295.

105. Starkstein SE, Rabins PV, Berthier ML, Cohen BJ, Folstein MF, Robinson RG. Dementia of depression among patients with neurological disorders and functional depression. J Neuropsychiatry Clin Neurosci 1989; 1(3):263-268.

106. Klaassen T, Verhey FR, Sneijders GH, Rozendaal N, de Vet HC, van Praag HM. Treatment of depression in Parkinson's disease: a meta-analysis. J Neuropsychiatry Clin Neurosci 1995; 7(3):281-286.

107. Shulman LM. Apathy in patients with Parkinson's disease. Int Rev Psychiatry 2000; 12:298-306.

108. Isella V, Melzi P, Grimaldi M, et al. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease. Mov Disord 2002; 17(2):366-371.

109. Richard IH, Schiffer RB, Kurlan R. Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci 1996; 8(4):383-392.

110. Higginson CI, Fields JA, Koller WC, Tröster AI. Questionnaire assessment potentially overestimates anxiety in Parkinson's disease. J Clin Psychol Med Settings 2001; 8(2):95-99.

111. Ryder KA, Gontkovsky ST, McSwan KL, Scott JG, Bharucha KJ, Beatty WW. Cognitive function in Parkinson's disease: association with anxiety but not depression. Aging Neuropsychol Cogn 2002; 9:77-84.

Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56(11 suppl 5):S1-S88. Tröster AI, Fields JA. The role of neuropsychological evaluation in the neurosurgical treatment of movement disorders. In: Tarsy D, Vitek JL, Lozano AM, eds. Surgical Treatment of Parkinson's Disease and Other Movement Disorders. Totowa, NJ: Humana Press, 2003:213-240.

Bedard MA, Pillon B, Dubois B, Duchesne N, Masson H, Agid Y. Acute and long-term administration of anticholinergics in Parkinson's disease: specific effects on the subcortico-frontal syndrome. Brain Cogn 1999; 40(2):289-313.

Bedard MA, Lemay S, Gagnon JF, Masson H, Paquet F. Induction of a transient dysex-ecutive syndrome in Parkinson's disease using a subclinical dose of scopolamine. Behav Neurol 1998; 11(4):187-195.

Koller WC. Disturbance of recent memory function in parkinsonian patients on anti-cholinergic therapy. Cortex 1984; 20(2):307-311.

Saint-Cyr JA, Taylor AE, Lang AE. Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology 1993; 43(Suppl. 6)(12):S47-52. Pondal M, Del Ser T, Bermejo F. Anticholinergic therapy and dementia in patients with Parkinson's disease. J Neurol 1996; 243(7):543-546.

McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356(9247):2031-2036.

Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16(6):1171-1174.

Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galan-tamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003; 18(10):937-941. Kaufer DI. Pharmacologic treatment expectations in the management of dementia with Lewy bodies. Dement Geriatr Cogn Disord 2004; 17(suppl 1):32-39. Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004; 19(1):1-8. Kulisevsky J. Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs Aging 2000; 16(5): 365-379.

Kulisevsky J, García-Sánchez C, Berthier ML, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 2000; 15(4):613-626.

Owen AM, Sahakian BJ, Hodges JR, Summers BA, Polkey CE, Robbins TW. Dopamine-dependent fronto-striatal planning deficits in early Parkinson's disease. Neuropsychol-ogy 1995; 9:126-140.

Fournet N, Moreaud O, Roulin JL, Naegele B, Pellat J. Working memory functioning in medicated Parkinson's disease patients and the effect of withdrawal of dopaminergic medication. Neuropsychology 2000; 14(2):247-253.

Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology 1992; 107(2-3):394-404. Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 2002; 125(Pt 3):584-594.

Stern Y, Mayeux R, Ilson J, Fahn S, Cote L. Pergolide therapy for Parkinson's disease: neurobehavioral changes. Neurology 1984; 34(2):201-204.

Brusa L, Tiraboschi P, Koch G, et al. Pergolide effect on cognitive functions in early-mild Parkinson's disease. J Neural Transm 2005; 112(2):231-237.

Cooper JA, Sagar HJ, Sullivan EV. Short-term memory and temporal ordering in early Parkinson's disease: effects of disease chronicity and medication. Neuropsychologia 1993; 31(9):933-949.

Weddell RA, Weiser, R. A double-blind cross-over placebo-controlled trial of the effects of bromocriptine on psychomotor function, cognition, and mood in de novo patients with Parkinson's disease. Behav Pharmacol 1995; 6:81-91.

134. Piccirilli M, Piccinin GL, D'Alessandro P, et al. Cognitive performances in parkinsonians before and after bromocriptine therapy. Acta Neurologica (Napoli) 1986; 8(3): 167-172.

135. Brusa L, Bassi A, Stefani A, et al. Pramipexole in comparison to l-dopa: a neuropsychological study. J Neural Transm 2003; 110(4):373-380.

136. Gasparini M, Fabrizio E, Bonifati V, Meco G. Cognitive improvement during Tolcapone treatment in Parkinson's disease. J Neural Transm 1997; 104(8-9):887-894.

137. Dixit SN, Behari M, Ahuja GK. Effect of selegiline on cognitive functions in Parkinson's disease. J Assoc Physicians India 1999; 47(8):784-786.

138. Finali G, Piccirilli M, Piccinin GL. Neuropsychological correlates of L-deprenyl therapy in idiopathic parkinsonism. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18(1): 115-128.

139. Hietanen MH. Selegiline and cognitive function in Parkinson's disease. Acta Neurologica Scandanavica 1991; 84(5):407-410.

140. Tarczy M, Szirmai I. Failure of dopamine metabolism: borderlines of parkinsonism and dementia. Acta Bio-Medica de l Ateneo Parmense 1995; 66(3-4):93-97.

141. Kieburtz K, McDermott M, Como P, et al. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Neurology 1994; 44(9):1756-1759.

142. Wilkinson SB, Tröster Al. Surgical interventions in neurodegenerative disease: impact on memory and cognition. In: Tröster AI, ed. Memory in Neurodegenerative Disease: Biological, Cognitive, and Clinical Perspectives. Cambridge, UK: Cambridge University Press, 1998:362-376.

143. Cahn DA, Sullivan EV, Shear PK, et al. Neuropsychological and motor functioning after unilateral anatomically guided posterior ventral pallidotomy. Preoperative performance and three-month follow-up. Neuropsychiatry Neuropsychol Behav Neurol 1998; 11(3):136-145.

144. de Bie RM, Schuurman PR, Bosch DA, de Haan RJ, Schmand B, Speelman JD. Outcome of unilateral pallidotomy in advanced Parkinson's disease: cohort study of 32 patients. J Neurol Neurosurg Psychiatry 2001; 71(3):375-382.

145. Green J, McDonald WM, Vitek JL, et al. Neuropsychological and psychiatric sequelae of pallidotomy for PD: clinical trial findings. Neurology 2002; 58(6):858-865.

146. York MK, Levin HS, Grossman RG, Hamilton WJ. Neuropsychological outcome following unilateral pallidotomy. Brain 1999; 122(Pt 12):2209-2220.

147. de Bie RM, de Haan RJ, Schuurman PR, Esselink RA, Bosch DA, Speelman JD. Morbidity and mortality following pallidotomy in Parkinson's disease: a systematic review. Neurology 2002; 58(7):1008-1012.

148. Scott R, Gregory R, Hines N, et al. Neuropsychological, neurological and functional outcome following pallidotomy for Parkinson's disease. A consecutive series of eight simultaneous bilateral and twelve unilateral procedures. Brain 1998; 121(Pt 4):659-675.

149. Scott RB, Harrison J, Boulton C, et al. Global attentional-executive sequelae following surgical lesions to globus pallidus interna. Brain 2002; 125(Pt 3):562-574.

150. Iacono RP, Carlson JD, Kuniyoshi S, Mohamed A, Meltzer C, Yamada S. Contemporaneous bilateral pallidotomy [electronic manuscript]. Neurosurgical Focus 1997; 2(3): Manuscript 5.

151. Ghika J, Ghika-Schmid F, Fankhauser H, et al. Bilateral contemporaneous posteroven-tral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects. Report of four cases and review of the literature. J Neurosurg 1999; 91(2):313-321.

152. Trepanier LL, Kumar R, Lozano AM, Lang AE, Saint-Cyr JA. Neuropsychological outcome of GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson's disease. Brain Cogn 2000; 42(3):324-347.

153. Fukuda M, Kameyama S, Yoshino M, Tanaka R, Narabayashi H. Neuropsychological outcome following pallidotomy and thalamotomy for Parkinson's disease. Stereotact Funct Neurosurg 2000; 74(1):11-20.

154. Hugdahl K, Wester K. Neurocognitive correlates of stereotactic thalamotomy and thal-amic stimulation in Parkinsonian patients. Brain Cogn 2000; 42(2):231-252.

155. Alvarez L, Macias R, Guridi J, et al. Dorsal subthalamotomy for Parkinson's disease. Mov Disord 2001; 16(1):72-78.

McCarter RJ, Walton NH, Rowan AF, Gill SS, Palomo M. Cognitive functioning after sub-thalamic nucleotomy for refractory Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 69(1):60-66.

Fields JA, Tröster Al. Cognitive outcomes after deep brain stimulation for Parkinson's disease: a review of initial studies and recommendations for future research. Brain Cogn 2000; 42(2):268-293.

Merello M, Nouzeilles Ml, Kuzis G, et al. Unilateral radiofrequency lesion versus electrostimulation of posteroventral pallidum: a prospective randomized comparison. Mov Disord 1999; 14(1):50-56.

Tröster Al, Fields JA, Wilkinson SB, et al. Unilateral pallidal stimulation for Parkinson's disease: neurobehavioral functioning before and 3 months after electrode implantation. Neurology 1997; 49(4):1078-1083.

Vingerhoets G, van der Linden C, Lannoo E, et al. Cognitive outcome after unilateral pallidal stimulation in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 66(3):297-304. Ardouin C, Pillon B, Peiffer E, et al. Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients. Ann Neurol 1999; 46(2):217-223.

Fields JA, Tröster Al, Wilkinson SB, Pahwa R, Koller WC. Cognitive outcome following staged bilateral pallidal stimulation for the treatment of Parkinson's disease. Clin Neurol Neurosurg 1999; 101(3):182-188.

Pillon B, Ardouin C, Damier P, et al. Neuropsychological changes between "off " and "on" STN or GPi stimulation in Parkinson's disease. Neurology 2000; 55(3):411-418. Dujardin K, Krystkowiak P, Defebvre L, Blond S, Destee A. A case of severe dysexecu-tive syndrome consecutive to chronic bilateral pallidal stimulation. Neuropsychologia 2000; 38(9):1305-1315.

Caparros-Lefebvre D, Blond S, Pécheux N, Pasquier F, Petit H. Evaluation neuropsychologique avant et après stimulation thalamique chez 9 parkinsoniens. Revue Neurologique 1992; 148(2):117-122.

Tröster Al, Wilkinson SB, Fields JA, Miyawaki K, Koller WC. Chronic electrical stimulation of the left ventrointermediate (Vim) thalamic nucleus for the treatment of pharmacotherapy-resistant Parkinson's disease: a differential impact on access to semantic and episodic memory? Brain Cogn 1998; 38(2):125-149.

Woods SP, Fields JA, Lyons KE, et al. Neuropsychological and quality of life changes following unilateral thalamic deep brain stimulation in Parkinson's disease: a 12-month follow-up. Acta Neurochirurgica 2001; 143:1273-1278.

Deuschl G, Herzog J, Kleiner-Fisman G, et al. Deep brain stimulation: postoperative issues. Mov Disord 2006; 21(14):S219-S237.

Woods SP, Fields JA, Tröster Al. Neuropsychological sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a critical review. Neuropsychol Rev 2002; 12(2):111-126.

Martínez-Martín P, Valldeoriola F, Tolosa E, et al. Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease. Mov Disord 2002; 17(2):372-377. Trott CT, Fahn S, Greene P, et al. Cognition following bilateral implants of embryonic dopamine neurons in PD: A double blind study. Neurology 2003; 60(12):1938-1943. Stocchi F, Brusa L. Cognition and emotion in different stages and subtypes of Parkinson's disease. J Neurol 2000; 247(suppl 2): 114-121.

Mark MH. Lumping and splitting the Parkinson plus syndromes: dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, and cortical-basal gan-glionic degeneration. Neurol Clin 2001; 19(3):607-627.

Dubois B, Pillon B, Legault F, Agid Y, Lhermitte F. Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson's disease. Arch Neurol 1988; 45(11):1194-1199.

Maher ER, Smith EM, Lees AJ. Cognitive deficits in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). J Neurol Neurosurg Psychiatry 1985; 48(12): 1234-1239.

Pillon B, Gouider-Khouja N, Deweer B, et al. Neuropsychological pattern of striatoni-gral degeneration: comparison with Parkinson's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1995; 58(2):174-179.

177. Soliveri P, Monza D, Paridi D, et al. Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2000; 69(3):313-318.

178. Cordato NJ, Pantelis C, Halliday GM, et al. Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain 2002; 125(Pt 4):789-800.

179. Robbins TW, James M, Owen AM, et al. Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. J Neurol Neurosurg Psychiatry 1994; 57(1):79-88.

180. Dubois B, Deweer B, Pillon B. The cognitive syndrome of progressive supranuclear palsy. Adv Neurol 1996; 69:399-403.

181. Grafman J, Litvan I, Stark M. Neuropsychological features of progressive supranuclear palsy. Brain Cogn 1995; 28(3):311-320.

182. Testa D, Monza D, Ferrarini M, Soliveri P, Girotti F, Filippini G. Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy. Neurolog Sci 2001; 22(3):247-251.

183. Quinn N, Wenning G. Multiple system atrophy. Curr Opin Neurol 1995; 8(4):323-326.

184. Berciano J. Olivopontocerebellar atrophy. A review of 117 cases. J Neurol Sci 1982; 53(2):253-272.

185. Deguchi K, Takeuchi H, Sasaki I, Tsukaguchi M, Touge T, Nishioka M. Impaired novelty P3 potentials in multiple system atrophy-correlation with orthostatic hypotension. J Neurol Sci 2001; 190(1-2):61-67.

186. Meco G, Gasparini M, Doricchi F. Attentional functions in multiple system atrophy and Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; 60(4):393-398.

187. Pirtosek Z, Jahanshahi M, Barrett G, Lees AJ. Attention and cognition in bradykinetic-rigid syndromes: an event-related potential study. Ann Neurol 2001; 50(5):567-573.

188. Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration. A clinical study of 36 cases. Brain 1994; 117(Pt 5):1183-1196.

189. Grimes DA, Lang AE, Bergeron CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 1999; 53(9):1969-1974.

190. Stover NP, Watts RL. Corticobasal degeneration. Semin Neurol 2001; 21(1):49-58.

191. Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological functioning in cortical-basal ganglionic degeneration: Differentiation from Alzheimer's disease. Neurology 1996; 46(3):720-726.

192. Graham NL, Bak TH, Hodges JR. Corticobasal degeneration as a cognitive disorder. Mov Disord 2003; 18(11):1224-1232.

193. Beatty WW, Scott JG, Wilson DA, Prince JR, Williamson DJ. Memory deficits in a demented patient with probable corticobasal degeneration. J Geriatr Psychiatry Neurol 1995; 8(2):132-136.

Was this article helpful?

0 0
Getting to Know Anxiety

Getting to Know Anxiety

Stop Letting Anxiety Rule Your Life And Take Back The Control You Desire Right Now! You don't have to keep letting your anxiety disorder run your life. You can take back your inner power and change your life for the better starting today! In order to have control of a thing, you first must understand it. And that is what this handy little guide will help you do. Understand this illness for what it is. And, what it isn't.

Get My Free Ebook


Post a comment